TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Liminatus Pharma ( (LIMN) ) has shared an announcement.
On July 10, 2025, Liminatus Pharma, Inc. expanded its board of directors to six members by appointing Philip Lemons and Richard Baek as new directors. Philip Lemons, aged 54, brings over two decades of experience in clinical research and development, having held leadership roles in various global research institutions and consulting firms. Richard Baek, aged 33, offers expertise in financial oversight, internal controls, and regulatory compliance, with a background in finance roles across multiple sectors. These appointments are expected to enhance the company’s strategic direction and governance.
More about Liminatus Pharma
Average Trading Volume: 328,147
Technical Sentiment Signal: Sell
Current Market Cap: $135.8M
For detailed information about LIMN stock, go to TipRanks’ Stock Analysis page.